BRCA1 and breast carcinoma: PARP-inhibitor treatment has proven effective for breast cancer (BC) patients with germline BRCA1/2 mutations, with a focus shifting from treatment in the metastatic setting more towards adjuvant treatment in the primary setting [1–4].